Lead Product(s) : Loxapine Succinate,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : CNX Therapeutics
Deal Size : $61.3 million
Deal Type : Divestment
Eisai Divests Rights to Loxapac and Parkinane LP to CNX Therapeutics
Details : Through the divestment, the company has acquired the rights and will concentrate on commercializing Loxacin (loxapine succinate) for treating psychotic disorders and personality disorders.
Product Name : Loxapac
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 04, 2024
Lead Product(s) : Loxapine Succinate,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : CNX Therapeutics
Deal Size : $61.3 million
Deal Type : Divestment
Lead Product(s) : Loxapine Succinate,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 09, 2014
Lead Product(s) : Loxapine Succinate,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
